United States Frontotemporal Dementia Market to Experience Steady Growth Through 2028
March 28, 2024 17:56 ET
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
Global Cognition and Memory Enhancement Market to 2026 - Featuring Nordic Naturals, Natrol and Cambridge Cognition Among Others
June 13, 2022 06:13 ET
|
Research and Markets
Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive...
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19
February 28, 2022 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
December 05, 2019 06:58 ET
|
Aptinyx Inc.
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
Study: Brain Training Addresses ICU-induced Cognitive Impairment and Delirium
June 26, 2018 08:00 ET
|
Posit Science
SAN FRANCISCO, June 26, 2018 (GLOBE NEWSWIRE) -- In a treatment breakthrough that could lead to a large impact on the speed and cost of recovery following patient stays in intensive care units...
Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment
May 01, 2018 10:31 ET
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....
Alzheimer’s Virtual Reality Sensory Experience Featured at Upcoming ASA Workshop
March 23, 2018 09:31 ET
|
Alzheimer's Foundation of America
SAN FRANCISCO, March 23, 2018 (GLOBE NEWSWIRE) -- The Alzheimer’s Foundation of America (AFA)—in collaboration with Greener Media—is hosting a workshop titled, "What Would You Do: A Sensory...
DiamiR to Present at the GTCbio Biomarker Summit 2017
March 20, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 20, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira...
DiamiR Awarded $2.75M Grant for Development of CogniMIR(TM) for Early Detection of Alzheimer's Disease
March 15, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 15, 2017) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...
Study Shows First Practical Intervention For Chemobrain
October 31, 2016 16:00 ET
|
Posit Science
SAN FRANCISCO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- For the first time, symptoms of cancer-related cognitive decline – often called “chemobrain” – were reversed in a large, home-based,...